Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07676266 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

StatusNot Yet Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The Affiliated Hospital of Qingdao University
48 trials monitored
See 1 trial at risk
Multiple Sclerosis
1,011 trials monitored
See 34 trials at risk
Lupus (SLE)
666 trials monitored
See 25 trials at risk
Scleroderma
324 trials monitored
See 13 trials at risk
and 1 more disease
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Trial Details
NCT Number NCT07676266
Lead Sponsor The Affiliated Hospital of Qingdao University
Collaborators: Shanghai AbelZeta Ltd.
Conditions
(from sponsor)		 Multiple Sclerosis (MS), Myasthenia Gravis (MG), Neuromyelitis Optica Spectrum Disorder, Systemic Lupus Erythematosus, Systemic Sclerosis, Immune-Mediated Necrotizing Myopathy
Related terms Lupus Erythematosus, Systemic, Multiple Sclerosis, Myasthenia Gravis, Neuromyelitis Optica, Scleroderma, Systemic
Enrollment 18 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov